Fig. 6: Twice-daily gavage of SerBut post-EAE induction suppressed disease progression.

a, Experimental schema. EAE was induced in C57BL/6 mice using MOG_35–55/CFA with pertussis toxin (140 ng). On day 2 after EAE induction, PBS (n = 9) or SerBut (n = 8) at 24 mg per dose was administered twice daily by gavage. b, Disease progression as indicated by the clinical score. The areas under the curve were compared, and statistical analyses were performed using Student’s t-test. c, The probability of EAE clinical scores remaining below 1.0 in the two groups. Statistical analysis was performed using the log-rank (Mantel–Cox) test. d, Body weight changes. e, Representative immunofluorescence images of spinal cord sections from mice treated with PBS or SerBut. Red, anti-CD45 staining; green, anti-MBP staining. f, The concentration of IFNγ normalized by the total protein in the spinal cord homogenized supernatant. g–l, The percentage of CD45⁺ (g), CD45⁺CD3⁺ (h), RORγt⁺CD4⁺ (i), CD11c^hi (j), CD11b⁺CD11c⁻ (k) and F4/80⁺CD11b⁺ (l) of live cells in the spinal cord. m–o, The percentage of MHCII⁺ of CD11c^hi (m), CD11b⁺CD11c⁻ (n) or F4/80⁺CD11b⁺ (o) cells in the spinal cord. Data represent mean ± s.e.m. Experiments were repeated with similar, though not identical, dosing regimens, and the results were consistent. Statistical analyses were performed using Student’s t-test.

Source data